If you enjoy this content, please share it with a colleague
Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.
RELATED CONTENT
Elekta and Royal Philips announced that The Institute of Cancer Research, London, a world-leading cancer research institution, working with its clinical partner The Royal Marsden NHS Foundation Trust, will join the Elekta MR Linac Research Consortium, a group with a mission to develop an integrated magnetic resonance imaging (MRI)-guided radiation therapy system.
June 11, 2014 — Erasmus University Medical Center (Erasmus MC) in Rotterdam, the Netherlands, announced the purchase of Elekta Versa HD linear accelerators (linacs) and a software upgrade including the Mosaiq oncology information system (OIS) and Monaco 5 treatment planning system.
June 3, 2014 — Elekta announced it signed an agreement to provide the Centre Hospitalier de l'Universite de Montreal (University of Montreal Health Centre, or CHUM) with advanced linear accelerators and software. The order, resulting from a competitive tender process, is valued at more than $20 million USD.
The radiation therapy market, hit hard in 2009 by the recession, saw a sharp decline in purchasing from which it has slowly recovered. During the last five years the market has been steadily growing, with capital equipment budgets for radiation oncology sites increasing. However, it has only been within the last year that equipment purchases for radiation therapy have leveled out. Purchasing decisions today are driven by two main factors: advancements in technology, including more targeted treatment, multifunctional capabilities and improved patient safety; and the evolving reimbursement model, which weighs patient outcomes and the quality of care delivered more heavily.
May 19, 2014 — A Japanese multi-institutional study1 of 1,194 patients, has found that individuals with five to 10 tumors treated with Gamma Knife stereotactic radiosurgery alone (no whole brain radiation therapy) fared as well as a group with two to four tumors who received this radiosurgery-only treatment.
Elekta has established a Center of Excellence program that seeks the collaboration of its clinical customers in the development of high-quality research, education and outreach to advance the treatment of cancer and brain disorders.
Elekta, Royal Philips and University Medical Center (UMC) Utrecht (the Netherlands) announced that the initial components of the world's first high-field magnetic resonance imaging (MRI) guided radiation therapy system are being installed at UMC Utrecht.
A 67-year-old male patient received his final Esteya electronic brachytherapy session to treat a squamous cell carcinoma on his right hand, Jan. 14. He was the first patient in the United States to receive Esteya treatment, which was delivered at a Los Gatos, California clinic by Rakesh Patel, M.D., medical director, The Targeted Radiation Institute. Since Patel began treatment of the patient in late December, he has added nine additional patients to the Esteya schedule.
Elekta demonstrated new features in its Mosaiq oncology information system (OIS) at HIMSS14. Elekta highlighted functionality optimized for today's rapidly consolidating oncology care delivery systems.
Oceania Oncology implemented Elekta’s Monaco 5 treatment planning system. Radiation therapy staff at Oceania's clinics in Maroochydore and Bundaberg began training on Monaco 5 in December 2013 and anticipated clinical use to begin in January 2014.